Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPT1A | P50416 | 9/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MVD | P53602 | 2/20 | 0.46 |
| ▸ | CPT2 | P23786 | 8/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | ACE | P12821 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6787712 | 1.00 | CPT1A (0.51) | CPT1AALDH1A1KMT2AMVDCPT2 | |
| SCHEMBL6793317 | 0.91 | MVD (0.53) | CPT1AALDH1A1KMT2AMVDCPT2 | |
| SCHEMBL6793326 | 0.91 | MVD (0.53) | CPT1AALDH1A1KMT2AMVDCPT2 | |
| SCHEMBL6794561 | 0.87 | ALDH1A1 (0.49) | CPT1AALDH1A1KMT2AMVDCPT2 | |
| SCHEMBL6794566 | 0.87 | ALDH1A1 (0.49) | CPT1AALDH1A1KMT2AMVDCPT2 | |
| SCHEMBL6783067 | 0.86 | KMT2A (0.49) | CPT1AALDH1A1KMT2AMVDCPT2 | |
| SCHEMBL6783077 | 0.86 | KMT2A (0.49) | CPT1AALDH1A1KMT2AMVDCPT2 | |
| SCHEMBL3187180 | 0.85 | ALDH1A1 (0.61) | CPT1AALDH1A1KMT2AMVDCPT2 | |
| SCHEMBL3187156 | 0.85 | ALDH1A1 (0.61) | CPT1AALDH1A1KMT2AMVDCPT2 | |
| SCHEMBL6788116 | 0.85 | KMT2A (0.53) | CPT1AALDH1A1KMT2AMVDCPT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6103910-A | FOR TREATMENT OF DISEASES ASSOCIATED WITH AMYLOIDOSIS, SUCH AS ALZHEIMER'S DISEASE, DIABETES MELLITUS, FAMILIAL AMYLOID POLYNEUROPATHY, SCRAPIE, AND KREUZFELD-JACOB DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2000-08-15 | — | — | US | claimed |
| US-6740760-B2 | SUCH AS 1-((S)-3-MERCAPTO-2-METHYL-PROPIONYL)-(R)-PYRROL-IDINE-2-CARBOXYLIC ACID FOR TREATING DISEASES ASSOCIATED WITH AMYLOIDOSIS (ALZHEIMER'S DISEASE, DIABETES, AND FAMILIAL AMYLOID POLYNEUROPATHY) | HOFFMANN-LA ROCHE INC. | 2004-05-25 | — | — | US | disclosed |
| US-20030100770-A1 | Such as 1-((S)-3-mercapto-2-methyl-propionyl)-(R)-pyrrol-idine-2-carboxylic acid for treating diseases associated with amyloidosis (Alzheimer's disease, diabetes, and familial amyloid polyneuropathy) | PENTRAXIN THERAPEUTICS LTD. (GB) | 2003-05-29 | — | — | US | disclosed |
| US-6512001-B1 | To treat diseases associated with amyloidosis, such as Alzheimer's disease | HOFFMANN-LA ROCHE INC. | 2003-01-28 | — | — | US | disclosed |
| EP-0915088-B1 | D-Proline derivatives | HOFFMANN LA ROCHE (CH) | 2002-09-18 | — | — | EP | disclosed |
| US-6262089-B1 | USING THESE COMPOUNDS TO TREAT DISEASES ASSOCIATED WITH AMYLOIDOSIS, SUCH AS ALZHEIMER'S DISEASE, MATURITY ONSET DIABETES MELLITUS, FAMILIAL AMYLOID POLYNEUROPATHY, SCRAPIE, AND KREUZFELD-JACOB DISEASE. | HOFFMAN-LA ROCHE INC. | 2001-07-17 | — | — | US | disclosed |
| US-6103910-A | FOR TREATMENT OF DISEASES ASSOCIATED WITH AMYLOIDOSIS, SUCH AS ALZHEIMER'S DISEASE, DIABETES MELLITUS, FAMILIAL AMYLOID POLYNEUROPATHY, SCRAPIE, AND KREUZFELD-JACOB DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2000-08-15 | — | — | US | disclosed |
| EP-0915088-A1 | D-Proline derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1999-05-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100770-A1 | Such as 1-((S)-3-mercapto-2-methyl-propionyl)-(R)-pyrrol-idine-2-carboxylic acid for treating diseases associated with amyloidosis (Alzheimer's disease, diabetes, and familial amyloid polyneuropathy) | PSEN1, PSEN2, IAPP | CPT1A 66/4885ALDH1A1 175/4885KMT2A 2513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.